Hennion & Walsh Asset Management, Inc. Phathom Pharmaceuticals, Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	SELL	$10.26 - $15.7 $99,224 - $151,834	-9,671 Reduced 16.49%	48,987 $507,000
Q2 2023 Aug 09, 2023	BUY	$7.28 - $14.32 $4,484 - $8,821	616 Added 1.06%	58,658 $840,000
Q1 2023 Apr 20, 2023	SELL	$6.19 - $12.36 $8,443 - $16,859	-1,364 Reduced 2.3%	58,042 $414,000
Q4 2022 Jan 12, 2023	BUY	$9.18 - $11.53 $43,467 - $54,594	4,735 Added 8.66%	59,406 $667,000
Q3 2022 Nov 14, 2022	SELL	$6.46 - $12.11 $11,841 - $22,197	-1,833 Reduced 3.24%	54,671 $606,000
Q2 2022 Jul 19, 2022	BUY	$6.2 - $15.5 $33,802 - $84,506	5,452 Added 10.68%	56,504 $477,000
Q1 2022 Apr 26, 2022	BUY	$11.55 - $20.06 $232,824 - $404,369	20,158 Added 65.25%	51,052 $695,000
Q4 2021 Feb 14, 2022	BUY	$17.83 - $33.15 $550,840 - $1.02 Million	30,894 New	30,894 $608,000

144

73.6M

42.3K

45.7K

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $294M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.